Primary Care Diabetes
Volume 1, Issue 3 , Pages 143-146 , September 2007

International survey of insulin pump users: Impact of continuous subcutaneous insulin infusion therapy on glucose control and quality of life

  • P. Hammond

      Affiliations

    • Department of Medicine, Harrogate District Hospital, Harrogate, UK
    • ,
  • A. Liebl

      Affiliations

    • Center for Diabetes and Metabolism, m&i-Fachklinik Bad Heilbrunn, Bad Heilbrunn, Germany
    • ,
  • S. Grunder

      Affiliations

    • Internal Medicine FMH, Disetronic Medical Systems AG, Roche Diabetes Care, Burgdorf, Switzerland
    • Corresponding Author InformationCorresponding author. Tel.: +41 34 424 2923; fax: +41 34 424 2400.

Received 17 April 2007 ,Revised 21 June 2007 ,Accepted 9 July 2007.

References 

  1. The Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993;329:977–986
  2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  3. Hoogma RP, Hammond PJ, Gomis R, et al. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial. Diab. Med. 2006;23:141–147
  4. Wainstein J, Metzger M, Boaz M, et al. Insulin pump therapy vs. multiple daily injections in obese Type 2 diabetic patients. Diab. Med. 2005;22:1037–1046
  5. DeVries JH, Snoek FJ, Kostense PJ, et al. A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycaemic control. Diab. Care. 2002;25:2074–2080
  6. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomized controlled trials. BMJ. 2002;324:1–6
  7. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diab. Care. 2003;26:1079–1087
  8. Siebenhofer A, Plank J, Berghold A, et al. Meta-analysis of short-acting insulin analogues in adult patients with type 1 diabetes: continuous subcutaneous insulin infusion versus injection therapy. Diabetologia. 2004;47:1895–1905
  9. Strowig SM, Raskin P. Improved glycaemic control in intensively treated type 1 diabetic patients using blood glucose meters with storage capability and computer-assisted analyses. Diab. Care. 1998;21:1694–1698
  10. Linkeschova R, Raoul M, Bott U, et al. Less severe hypoglycaemia, better metabolic control, and improved quality of life in Type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. Diab. Med. 2002;19:746–751
  11. Schiffers T. Quality of life with intensive insulin therapy: a prospective comparison of insulin pen and pump. Psychother. Psychosom. Med. Psychol. 1997;7:49–54

PII: S1751-9918(07)00077-0

doi: 10.1016/j.pcd.2007.07.005

Primary Care Diabetes
Volume 1, Issue 3 , Pages 143-146 , September 2007

Article Tools

* Image Usage & Resolution